Clearpoint Neuro Inc (CLPT) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Clearpoint Neuro Inc   (NASDAQ: CLPT)

Select the Financial Report: Select the Period:


Description of Clearpoint Neuro Inc's Business Segments


Clearpoint Neuro Inc. is a medical technology company that specializes in the development and commercialization of innovative solutions for neurological procedures. Its primary focus is on advancing the precision and effectiveness of neurosurgery through its specialized products and services tailored for neuro-targeting and guidance in surgical procedures. Below is an extensive description of the segments, products, and services Clearpoint Neuro Inc. offers:

Segments

1. Neurosurgery and Neuro-navigation: Clearpoint Neuro operates primarily in this segment, focusing on providing tools and technologies that enhance the surgeons ability to accurately target brain structures during procedures.

2. Research & Development: This segment encompasses ongoing efforts aimed at developing new technologies and improving existing systems. The company invests in R&D to enhance neuro-surgical techniques and expand the applications of its products.

3. Clinical Services: Clearpoint Neuro provides clinical services to healthcare facilities, offering support and training for healthcare professionals using its systems and ensuring the effective integration of its technologies into clinical practice.

Products

1. ClearPoint® Neuro Navigation System:
- A comprehensive intra-operative navigation system designed for use in neurosurgery. It provides real-time guidance for various procedural approaches including biopsies, electrode placements, and drug delivery.
- Features touchscreen interfaces and integration with imaging technologies for enhanced navigational accuracy during surgical procedures.

2. ClearPoint® Catheter System:
- A disposable catheter system specifically designed for minimally invasive access to the brain.
- It allows for precise placement within the brain tissue for therapeutic delivery, such as drugs or other treatments, aimed at various neurological disorders.

3. SmartFlow® Technology:
- A unique flow management system that integrates with the ClearPoint Neuro Navigation System, enabling controlled delivery of therapies directly to the targeted brain area.
- It helps maximize the efficacy of drugs while minimizing systemic exposure to pharmacological agents.

4. Guidance and Treatment Solutions:
- This includes systems and protocols for guiding neuronavigational procedures, enhancing the accuracy of therapies such as deep brain stimulation (DBS) and tumor resections.

Services

1. Training and Education:
- Clearpoint Neuro offers comprehensive training programs for neurosurgeons and clinical staff, focusing on how to effectively use their navigation systems and catheters during surgery.
- Educational resources also include workshops, webinars, and demonstrations aimed at familiarizing users with the latest techniques and applications of their technologies.

2. Technical Support:
- The company provides continuous technical support and consulting services to healthcare facilities. This includes troubleshooting, system maintenance, and upgrades, ensuring the equipment operates optimally during critical procedures.
- Customers can access knowledgeable support staff to assist with any technical queries or challenges they may encounter.

3. Clinical Collaboration:
- Clearpoint Neuro engages in collaborations with research institutions, hospitals, and healthcare practitioners to conduct clinical studies aimed at evaluating and validating new applications of their products.
- These partnerships foster innovation and contribute to the body of knowledge in neurosurgery, allowing for the development of better treatment protocols and technologies.

4. Post-Operative Support:
- After surgical procedures, Clearpoint provides follow-up support to ensure that patients receive the maximum benefit from the therapies delivered and that any complications are addressed promptly.
- This also involves gathering feedback from healthcare providers to continuously refine and improve products and service offerings.

Conclusion

Clearpoint Neuro Inc. focuses on enhancing the precision and safety of neurosurgical procedures through its array of products and services. With an emphasis on innovative technology, extensive training, and solid clinical support, the company aims to empower healthcare professionals and improve patient outcomes within the field of neurology.


Composition of Clearpoint Neuro Inc Revenues by Segments

 
Biologics and drug delivery    39.64 % of total Revenue
Biologics and Drug Delivery - Disposable Products    15.63 % of total Revenue
Biologics and Drug Delivery - Services and License Fees    24.02 % of total Revenue
Neurosurgery navigation and therapy    48.54 % of total Revenue
Neurosurgery Navigation and Therapy - Disposable Products    48.54 % of total Revenue
Capital equipment and software    11.82 % of total Revenue
Capital Equipment and Software - Systems and Software Products    8.41 % of total Revenue
Capital Equipment and Software - Services    3.41 % of total Revenue
Capital Equipment and Software-Related Service    18.96 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Biologics and drug delivery 4.81 39.64 %
Biologics and Drug Delivery - Disposable Products 1.90 15.63 %
Biologics and Drug Delivery - Services and License Fees 2.91 24.02 %
Neurosurgery navigation and therapy 5.89 48.54 %
Neurosurgery Navigation and Therapy - Disposable Products 5.89 48.54 %
Capital equipment and software 1.43 11.82 %
Capital Equipment and Software - Systems and Software Products 1.02 8.41 %
Capital Equipment and Software - Services 0.41 3.41 %
Capital Equipment and Software-Related Service 2.30 18.96 %
Total 12.13 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Biologics and drug delivery 2.49 % -
Biologics and Drug Delivery - Disposable Products 6.46 % -
Biologics and Drug Delivery - Services and License Fees 0.07 % -
Neurosurgery navigation and therapy 79.65 % -
Neurosurgery Navigation and Therapy - Disposable Products 79.65 % -
Capital equipment and software 177.18 % -
Capital Equipment and Software - Systems and Software Products 335.9 % -
Capital Equipment and Software - Services 45.94 % -
Capital Equipment and Software-Related Service 187.5 % -
Total 42.93 % -67.2 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total -9.55 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Clearpoint Neuro Inc Divisions, Sales by Country

 
Biologics and drug delivery   Biologics and drug delivery Segment contribution to total sales 51.5 % of total Revenue
Biologics and Drug Delivery - Disposable Products   Biologics and Drug Delivery - Disposable Products Segment contribution to total sales 19.85 % of total Revenue
Biologics and Drug Delivery - Services and License Fees   Biologics and Drug Delivery - Services and License Fees Segment contribution to total sales 31.65 % of total Revenue
Neurosurgery navigation and therapy   Neurosurgery navigation and therapy Segment contribution to total sales 40.12 % of total Revenue
Neurosurgery Navigation and Therapy - Disposable Products   Neurosurgery Navigation and Therapy - Disposable Products Segment contribution to total sales 40.12 % of total Revenue
Capital equipment and software   Capital equipment and software Segment contribution to total sales 8.38 % of total Revenue
Capital Equipment and Software - Systems and Software Products   Capital Equipment and Software - Systems and Software Products Segment contribution to total sales 4.57 % of total Revenue
Capital Equipment and Software - Services   Capital Equipment and Software - Services Segment contribution to total sales 3.81 % of total Revenue
Capital Equipment and Software-Related Service   Capital Equipment and Software-Related Service Segment contribution to total sales 5.68 % of total Revenue


Twelve months ended 2025
CLPT s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Biologics and drug delivery 19.04 51.5 %
Biologics and Drug Delivery - Disposable Products 7.34 19.85 %
Biologics and Drug Delivery - Services and License Fees 11.70 31.65 %
Neurosurgery navigation and therapy 14.83 40.12 %
Neurosurgery Navigation and Therapy - Disposable Products 14.83 40.12 %
Capital equipment and software 3.10 8.38 %
Capital Equipment and Software - Systems and Software Products 1.69 4.57 %
Capital Equipment and Software - Services 1.41 3.81 %
Capital Equipment and Software-Related Service 2.10 5.68 %
Total 36.97 100 %


Twelve months ended 2025
CLPT s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -25.54 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Biologics and drug delivery 9.99 % -
Biologics and Drug Delivery - Disposable Products 30.9 % -
Biologics and Drug Delivery - Services and License Fees -0.02 % -
Neurosurgery navigation and therapy 44.2 % -
Neurosurgery Navigation and Therapy - Disposable Products 44.2 % -
Capital equipment and software -18.31 % -
Capital Equipment and Software - Systems and Software Products -38.21 % -
Capital Equipment and Software - Services 33.02 % -
Capital Equipment and Software-Related Service -8.7 % -
Total 17.78 % -
Capital Equipment Related Service Revenue - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.